Hepatitis B immune globulin - Biotest AG

Drug Profile

Hepatitis B immune globulin - Biotest AG

Alternative Names: BT-088; Fovepta; HBVIg - Biotest AG; Hepatect; Hepatect CP; Hepatect FH; Human hepatitis B immunoglobulin - Biotest AG; Neohepatect; Zutectra

Latest Information Update: 05 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotest AG
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 23 Apr 2015 Biotest files an MAA application with the EMA in European Union early use hepatitis B immunoglobulin in Hepatitis B (prevention of relapse in liver transplant patients)
  • 23 Apr 2015 Efficacy and adverse events data from the phase III ZEUS trial in Hepatitis B (prevention of relapse in liver transplant patients) released by Biotest
  • 01 Jan 2013 Merz Pharma acquires marketing rights for Neohepatect® in Russia, from Biotest AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top